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ABSTRACT Amphetamine and its derivatives are important drugs of abuse causing
both short-term excitatory and long-term addictive effects. The short-term excitatory
effects are linked to amphetamine’s ability to maintain high levels of dopamine (DA) out-
side the cell both by inhibiting DA reuptake after synaptic transmission and by enhanc-
ing the efflux of DA from the dopaminergic cells. The molecular mechanisms by which
amphetamine elicits the efflux of DA and similar monoamines are still unclear. Recent
literature data suggest that trafficking of the monoamine transporters is a phenomenon
that underlies observed changes in amphetamine-induced monoamine reuptake and
efflux. We develop an ordinary differential equation model incorporating the diverse
mechanistic details behind amphetamine-induced DA efflux and demonstrate its utility
in describing our experimental data. We also demonstrate an experimental method to
track the time-varying concentration of membrane-bound transporter molecules from
the DA efflux data. The good fit between our model and the experimental data sup-
ports the hypothesis that amphetamine-induced transporter trafficking is necessary
to produce extended efflux of DA. This model can explain the relative significance
of different processes associated with DA efflux at different times and at different
concentration ranges of amphetamine and DA. Synapse 61:500–514, 2007. VC 2007
Wiley-Liss, Inc.
INTRODUCTION
The localization of dopamine (DA) in limbic and
hypothalamic tracts, as well as basal ganglia, inte-
grally involves DA in crucial functions, such as cogni-
tion, reward, hormonal regulation, and movement.
Consequently, DA plays key roles in the pathology of
psychosis, drug abuse, and Parkinson’s disease. The
regulation of the level of synaptic DA is thus extremely
important for normal function. Although exocytotically
released DA is inactivated by metabolism, by diffusion
and by reuptake, the key regulator of synaptic DA is
considered to be reuptake through the Naþ, Cl-de-
pendent plasmalemmal dopamine transporter (DAT),
DAT (Zahniser and Doolen, 2001). DAT is also the site
of action of two psychostimulant drugs, amphetamine
and cocaine. Both drugs competitively inhibit reuptake
of DA, but amphetamine functions as a substrate of
DATwhile cocaine blocks DAT (Seiden et al., 1993).
The Naþ, Cl-dependent transporters, including
DAT, are considered to function as gated carriers. In
that model, the substrate binds to a conformation of the
transporter with an open binding site facing the exte-
rior of the cell, followed by a subsequent conformational
change that \closes" the exterior site and \opens"
an interior site resulting in dissociation of substrate at
the opposite side (Rudnick and Clark, 1993; Schenk,
2002). This process is referred to as carrier-mediated
diffusion (Stein, 1986). The concept of inward- and out-
ward-facing gates of the Naþ, Cl-dependent transport-
ers is consistent with the solved crystal structure of a
bacterial homologue of Naþ, Cl-dependent transport-
ers, the LeuTAa transporter (Yamashita et al., 2005).
Transporter-mediated exchange has been hypothe-
sized to explain the mechanism of action of ampheta-
mine (Fischer and Cho, 1979; Seiden et al., 1993),
whereby amphetamine would bind to the exterior face
of the transporter and, upon being transported inward
along with Naþ and Cl, would increase the concentra-
tion of inward-facing transporter as well as the concen-
tration of Naþ at the inward face of the transporter. A
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consequence of this mechanism would be that one
molecule of DAwould be released for every molecule of
amphetamine taken up. However, results of several
studies are inconsistent with this simplistic model
and further understanding of the function and regula-
tion of DAT have led to a modification of the hypothesis
(Khoshbouei et al., 2004; Sitte et al., 1998) (and see
complete discussion in Sulzer et al., 2005). For in-
stance, DAT can also exist in a channel-like mode
whereby there is a greater transfer of charge than
anticipated by amount of transported substrate
(Kahlig et al., 2005; Sonders et al., 1997). Sulzer et al.
(2005) have postulated a unified theory of ampheta-
mine-stimulated reverse transport that is a gating
mechanism, which combines aspects of facilitated dif-
fusion with its one to one molecule limit with those of a
channel.
Another aspect of DAT regulation that can affect
influx and efflux characteristics is intracellular traf-
ficking (Gnegy, 2003; Khoshbouei et al., 2004; Zahniser
and Doolen, 2001). In heterologous PC12 cells, DAT
was shown to internalize at rates of 3–5% per minute
(Loder and Melikian, 2003), which greatly exceeds bulk
membrane turnover rates (Melikian, 2004). Second
messenger signaling has been demonstrated to have
profound effects on DAT activity through regulation of
surface DAT [for a comprehensive review, see (Zahniser
and Doolen, 2001)]. For example, activation of protein
kinase C for times greater than 10–15 min significantly
reduces DA uptake and, coordinately, reduces cell sur-
face DAT (for a complete review of this well-docu-
mented effect, see Zahniser and Doolen, 2001). On the
other hand, a short pulse of a protein kinase C-activat-
ing phorbol ester increases DA efflux through the DAT
(Cowell et al., 2000; Kantor and Gnegy, 1998). Amphet-
amine itself regulates trafficking of DAT in a biphasic
manner. At higher concentrations or longer times, am-
phetamine treatment of cells results in a reduction of
DA uptake and a reduction in surface DAT (Saunders
et al., 2000). However, we have demonstrated that, at
short times, amphetamine treatment of synaptosomes
or heterologous HEK 293 cells results in a significant
increase of surface DAT (Johnson et al., 2005). The
increase in surface DATwas found at times commensu-
rate with the action of amphetamine in eliciting DA
efflux.
The kinetic conditions of amphetamine-stimulated
DA efflux have been modeled based on principles of a
simple carrier as defined by Stein (1986), using either a
3-state (Jones et al., 1999) or 4-state model (Schenk,
2002). Because AMPH can alter both DAT trafficking
and DAT reversal simultaneously, though at different
rates and at different levels of intracellular AMPH and
DA, a quantitative model is required to understand
both the relative contributions of each to the overall
AMPH-induced DA efflux, and the temporal dynamics
of the process. In this article, we introduce AMPH-
induced DAT trafficking as a necessary component to
an existing AMPH-induced DAT reversal model for
understanding AMPH effects on DA efflux. The model
successfully describes AMPH-induced DA efflux in an
hDAT-transfected HEK 293 cell system and strongly
supports the need to include DAT trafficking in quanti-
tative modeling of DATefflux.
METHODS
We developed a mathematical model based on trans-
port kinetics to understand the effects of AMPH on DA
efflux and DAT trafficking and performed experiments
to measure some of the uptake and release parameters
of the model. This section explains the model develop-
ment and the experimental methods used.
Mathematical model
Figure 1 illustrates the processes associated with
AMPH-induced DA efflux. Both AMPH and DA are
structurally similar and are transported by DAT
through similar mechanisms (Fig. 1a, Box 1). DAT mol-
ecules on the plasma membrane constantly undergo
reorientation between their outward-facing and
inward-facing conformations. The ratio of these two
conformations regulates the net directional preference
of monoamine transport. The competitive transport of
AMPH through DAT affects this ratio of DAT conforma-
tions and subsequently leads to enhanced DA release.
DAT molecules undergo constitutive internalization
and may be degraded intracellularly (Daniels and
Amara, 1999). Intracellular DAT may also be mobilized
back to the surface (Loder and Melikian, 2003). Cur-
rent theories of AMPH-mediated DA release propose
that AMPH plays a significant role in this DAT traffick-
ing (internalization and surface mobilization).
Transport of DA and AMPH by DAT
DAT-mediated transport of monoamine neurotrans-
mitters across the plasma membrane occurs via three
sequential steps—binding, DAT reorientation, and
release. This transport can be oriented from inside to
outside or vice versa. The transported neurotrans-
mitters are slowly metabolized because of the action of
enzymatic degradation. Every time an extracellular
substrate molecule gets transported to the inside of the
cell through DAT, the DAT molecule reorients from an
outward-facing configuration to an inward-facing con-
figuration and vice versa. DAT can function bidirection-
ally to transport substrates from both inside and out-
side of the cell, though the transport efficiencies for the
influx and efflux may differ and depend on the DAT
conformation (Chen and Justice Jr, 2000; Khoshbouei
et al., 2004; Sitte et al., 1998; Stein, 1986). This bidirec-
tional functionality together with the reversal of the
transporter orientation during neurotransmitter trans-
port results in two distinct populations of fully func-
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tional transporter molecules oriented opposite to each
other that can cause influx and efflux of neurotrans-
mitters simultaneously. Thus, conditions that affect
the distribution of DAT molecules between these two
different populations will also affect the extents and
rates of influx and efflux.
The regulated bidirectional transport of DA through
DAT in a wild type cell confers the cell with the ability
to retain and to cause efflux of DA dependent on the
loading conditions (Wilhelm et al., 2006). The struc-
tural similarity of AMPH and DA favors a moderately
high affinity of AMPH for DAT (Liang and Rutledge,
1982; Wayment et al., 1998; Zaczek et al., 1991). Conse-
quently, AMPH can be transported in a similar fashion
through DAT. Under conditions of simultaneous trans-
port of DA and AMPH, the effects of AMPH on individ-
ual DAT molecules and on the overall population of
DAT molecules become critical. Initially, the effect of
AMPH transport through DAT to the cell interior is pri-
marily to reorient the membrane-bound DAT. Later,
AMPH is expected to affect the distribution of DAT
between the intracellular and membrane-bound
domains by mediating the trafficking of DAT mole-
cules. The effect of AMPH on DAT trafficking is highly
dependent on the intracellular concentration of AMPH
(Kahlig et al., 2006). These phenomena are captured
mathematically as described later.
Our semiempirical kinetic model is designed with
easily measurable monoamine concentrations as varia-
bles and we write ordinary differential equations to
describe how these concentrations change with time.
Both 3-state (Jones et al., 1999) and 4-state (Schenk,
2002; Wayment et al., 1998) models have been used to
describe DAT function; we use the 4-state model, which
includes both inward-facing and out-ward facing bound
conformations of DAT, for completeness. We write out
the individual transport terms in Michaelis–Menton
forms by lumping individual rate constants into Vmax
(comparable to the inverse of the resistance term in
Stein, 1986) and K parameters (Earles and Schenk,
1999). Also, for understanding the effect of AMPH on
DA efflux, we split the efflux term into two to delineate
the effects of AMPH from basal efflux.
The rate of change of DA concentration outside the
cell, [DAo], is given by
d½DAo
dt
¼ V1 ½DAt  ½DAof g
K1 þ ½DAt  ½DAof g
þ V2½AMPHo ½DAt  ½DAof g




The first term on the right-hand side of the equation
where [DAt] is the total amount of DA inside and out-
side the cell represents the \basal" efflux of DA in the
absence of any other monoamine; the second term
refers to the AMPH-mediated DA efflux and is based on
the ability of AMPH to induce reversal of DAT confor-
mation and subsequently to cause changes in DA trans-
port; the third term indicates the uptake of DA from
outside through the membrane-bound DAT. The
\basal" efflux is nonvarying and the AMPH-induced
efflux of DA is a function of time. Thus, the total efflux
of DA in the presence of AMPH is considered to be a
sum of this nonvarying basal efflux and the varying,
AMPH-induced efflux. The detailed derivation of the
Fig. 1. (a) Schematic of the processes by which AMPH affects DA
efflux and uptake. Box 1 refers to the membrane-bound processes
associated with AMPH-induced DAT reversal. The four states (bound
and unbound states of both the inward-facing and outward-facing con-
formations of DAT) shown represent the current model for explaining
the effects of AMPH on DA efflux. Box 2 refers to the processes associ-
ated with the trafficking of DAT to and from the membrane, including
internalization, surface mobilization, and degradation. DA is repre-
sented by filled circles and AMPH by open circles. (b) Four-state ki-
netic scheme for simultaneous transport of DA and AMPH through
the membrane-bound DAT. The rate constants for the individual steps
are indicated next to the arrows.
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first two terms is explained in the Appendix (Eq. A11a).
It is assumed that all transport of DA across the cell
membrane is DAT-mediated and does not occur
through processes such as exocytosis or endocytosis.
While both DA and AMPH may diffuse in and out of
the cell membrane depending on the concentration gra-
dient across the membrane, the extent of diffusional
transport in membrane systems expressing DAT is
expected to be very low. Sitte et al. (1998) showed that
the transport of DA and AMPH across the membrane in
DAT-expressing cells is significantly higher than in cells
without DATand is very sensitive to DAT-blocking mole-
cules like cocaine. In our model, we assume a completely
nonleaky model for the membrane with all the transport
of DA and AMPH regulated by membrane DAT.
In Eq. 1, the extracellular concentration of AMPH
can vary with experimental conditions. In such cases,
the rate of change of extracellular AMPH concentra-












The first two terms on the right-hand side of Eq. 2 rep-
resent the efflux rates of AMPH through DATwhile the
last term represents the uptake rate of AMPH. It is
assumed that since AMPH transport across the mem-
brane, like DA transport, is DAT-mediated, it also fol-
lows simple Michaelis–Menton kinetics. The middle
term in Eq. 2, representing the effect of DA on AMPH
transport, resembles the middle term in Eq. 1. In most
experimental measurements of DA efflux, the extracel-
lular concentration of DA is insignificant and hence the
middle term can be ignored.
In Eqs. 1 and 2, the V parameters (V1 through V5)
determine the maximal rates and lump quantities,
such as the number of surface transporters and the
dominant rate constants in the entire transport pro-
cess. The K parameters (K1 through K4) determine the
affinity and the efficiency of binding of the substrate
with the different transporter conformations and they
lump the rate constants for association and dissociation
events. More detail is given in the Appendix. The phys-
ical meanings of the parameters are listed in Table I
and the full expressions for the lumped parameters can
be seen in the Appendix.
DAT trafficking
If one were to assume that basal or constitutive traf-
ficking has no significant effect on the concentration of
membrane-bound DAT and that trafficking is unaf-
fected by intracellular AMPH, then the concentration
of membrane-bound DAT would remain constant. Con-
sequently, the V parameters that lump the membrane-
bound DAT concentration along with other rate con-
stants would also be constant. Quantitative models of
AMPH-induced DA efflux to date have included this
assumption (Earles and Schenk, 1999; Jones et al.,
1999).
However, if DAT trafficking is actively regulated, the
concentration of DAT at the membrane will change
with time. Thus the maximal transport rates, the V pa-
rameters in Eqs. 1 and 2, will become time-dependent
and can be expressed as
V1ðtÞ ¼ p1 ~nðtÞ ð3aÞ
V2ðtÞ ¼ p2 ~nðtÞ ð3bÞ
V3ðtÞ ¼ p3 ~nðtÞ ð3cÞ
where ~nðtÞ is a dimensionless number representing the
time-varying membrane-bound DAT concentration nor-
malized to the initial (before AMPH stimulation) mem-
brane-bound DAT concentration and p’s are lumped pa-
rameters representing the grouping of rate constants
(Eqs. A12 and A13) with the initial membrane-bound




¼ p1 ~nðtÞ ½DAt  ½DAof g
K1 þ ½DAt  ½DAof g
þ p2 ~nðtÞ½AMPHo ½DAt  ½DAof g




An expression for the time-variant ~nðtÞ can be written
in terms of the rate of surface mobilization and inter-
nalization of the transporter molecules. In the absence
of AMPH, we assume that DAT molecules are constitu-
tively internalized and mobilized at a constant rate and
hence do not vary much with time. In the presence of
AMPH, they are mobilized and internalized at a rate
dependent upon the concentration of intracellular










where the terms with () are obtained by normalizing
the respective rates to the initial (before AMPH stimu-
lation) membrane-bound DAT concentration. Table I
gives the definitions and physical meanings of the
parameters in Eq. 5.
Solution method
Equations 2, 4, and 5 can be solved simultaneously
usingMathematica (Wolfram Research Inc., Champaign,
IL) to obtain the time-varying extracellular DA concen-
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tration for a particular set of initial conditions. Appro-
priate choice of experimental conditions can simplify
the solution. The initial conditions for the concentra-
tion variables are typically one of four sets (zero-cis,
zero-trans, infinite-cis, or infinite-trans; cis is the intra-
cellular side and trans is the extracellular side). For
the experiments described in this article, the initial
conditions for AMPH-induced DA efflux are zero-trans
for DA (i.e., [DAo]t¼0 ¼ 0 and {[DAt]–[DAo]}t¼0 ¼ DA
loading in the cell), and zero-cis for AMPH (i.e.,
[AMPHi]t¼0 ¼ 0 and [AMPHo]t¼0 ¼ AMPH concentra-
tion used to stimulate DA efflux).
Experimental methods
Data for model fitting and analysis were obtained by
monitoring the time-dependent AMPH-induced DA
efflux in a continuous perfusion protocol. We also con-
ducted steady state DA efflux experiments in petri
dishes to explore some steady state characteristics of
the system.
Measurement of AMPH-induced DA efflux
Confluent HEK 293 cells stably transfected with
hDAT (hDAT-HEK described in Hastrup et al., 2001;
Khoshbouei et al., 2004) were cultured in 100-mm plates
and then incubated with 15 mM unlabeled DA for 30 min
at 378C. DA taken up during this incubation (loaded DA
amount) was measured by homogenizing and lysing the
suspended cells and measuring the DA content in the su-
pernatant by high-performance liquid chromatography
(HPLC) with electrochemical detection (HPLC-EC). The
total DA accumulated in the cells over the 15-min period
was 3000 pmol of DA/mg total protein. The total protein
content of the cells was measured by Bio-Rad DC Protein
Assay (Bio-Rad Laboratories, Hercules, CA). Following
incubation, cells were washed twice with a Krebs-
Ringer-Hepes (KRH) buffer (25 mM Hepes, pH 7.4, 125
mMNaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.3 mMCaCl2,
1.2 mM MgSO4, 5.6 mM glucose, and 1 mM tropolone)
and resuspended in 900 ml of the same. The cell suspen-
sion (800 ml) was equally split and loaded onto four dif-
ferent chambers in the Brandel superfusion apparatus
(Brandel SF-12, Gaithersburg, MD) and the remaining
100 ml of the cells were used to measure protein. The
cells were washed with KRH buffer for 30 min before
perfusion with either 0, 1, 3, or 10 mM AMPH for a full
50 min. The flow rate was 100 ml/min. DA released from
cells in response to AMPH stimulation was collected in
5-min intervals and analyzed using HPLC-EC. The
amount of DA collected at each 5-min interval was then
normalized to the total amount of DA loaded. To compare
the amount of DA collected from different perfusion
chambers, the amount of DA collected (expressed in
pmol released/pmol loaded) was then multiplied by the
average loading concentration of DA (3000 pmol DA/mg
TABLE I. List of parameters used in the model for AMPH-induced DA release





Lumped parameter of rate constants associated with basal





Lumped parameter of rate constants associated with
AMPH-induced DA efflux only, along with the initial
concentration of total membrane-bound DAT
s1 0.028
p3 Rate constants associated with DA uptake lumped with the
initial concentration of total membrane-bound DAT
pmol/mg/s 11.5
V4 Maximal uptake rate of AMPH through DAT pmol/mg/s 1
Ṽ6 Maximal rate of AMPH-induced surface mobilization of
DAT, normalized to the initial membrane-bound DAT
concentration before AMPH stimulation
s1 1
Ṽ7 Maximal AMPH-induced DAT internalization rate,
normalized to the initial membrane-bound DAT









Measure of affinity of DA to the inward-facing conformation
of DAT
pmol/mg 3500
K3 Measure of affinity of DA to the outward-facing conformation
of DAT
pmol/mg 410
K4 Measure of affinity of AMPH to the outward-facing
conformation of DAT
pmol/mg 50
K6 Measure of affinity of intracellular AMPH towards the
molecular machinery that mobilizes DAT to the membrane
from the cytosol
pmol/mg 28.336 1.67
K7 Measure of affinity of intracellular AMPH towards the
intracellular molecular machinery involved in the




Lumped parameter signifying the relative dominance of




Time constant signifying the effectiveness of AMPH release
process
s1 0.1
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total protein) to give amount of DA released in each
chamber in units of pmol of DA/mg total protein. The
variability between the chambers comes from the differ-
ence in the number of cells loaded in them. Further, for
comparison with the model, the amounts of DA released
in each of the successive 5-min intervals (Fig. 2a) were
added to give a cumulative amount of DA released over a
specific period of time (Fig. 2b).
Measurement of basal efflux of DA for different
loading concentrations
Confluent hDAT-HEK 293 cells were transferred
from flasks to 35-mm petri dishes and incubated with 2
ml of media containing 30 nM of [3H]DA (Perkin Elmer,
Boston, MA, specific activity 59.7 mCi/nmol) with vary-
ing concentrations of unlabeled DA (0.5, 1, 5 mM). Fol-
lowing incubation for 10 min at 378C, the media was
removed and the cells were washed twice with KRH
buffer. One milliliter of KRH buffer was added to the
culture dish. After 10 min, 200-ml aliquots of the media
were placed into ScintiVerse BD and the extracellular




Simple analyses of Eqs. 2, 4, and 5 can provide both
valuable insights into the behavior of the system under
particular circumstances and initial estimates for some
model parameters.
Basal DA efflux (no AMPH)
In the absence of AMPH (and hence ~n ¼ 1), the rate




¼ p1 ½DAt  ½DAof g




Many DA efflux experiments are performed in zero-
trans conditions and so the initial concentration of
extracellular DA is zero (i.e., [DAo]t¼0 ¼ 0). Under these
conditions, the DA efflux rate, measured as the rate of
change of extracellular DA concentration, is a maxi-
mum initially and gradually falls off as the intracellu-
lar DA levels are depleted. In the absence of reuptake,
complete emptying of the intracellular DA could be
expected. But there is also transport of DA back into
the cell through the same transporters. Consequently,
the DA efflux rate falls significantly even after a mod-
erate amount of efflux. As detailed later, these tempo-
ral dynamics simplify further for particular cases.
Moderate to low DA-transporter binding affin-
ity [large K value(s)]. We consider three cases. First,
if the K values on either side of the cell membrane are
significantly larger than the relevant DA concentra-
tions (i.e., K1  {[DAt]–[DAo]}) and K3  [DAo]), Eq. 6








Fig. 2. AMPH-induced DA efflux. (A) The amount of DA in
the extracellular perfusate, released from hDAT-HEK cells perfused
with 10 lM AMPH and measured at 5-min collection intervals, using
HPLC-EC. (B) Cumulative time-varying DA release for four perfusion
concentrations of AMPH (0, 1, 3, and 10 lM). The data points are
mean concentrations calculated from three cell populations and the











Such substrates (with large K values) typically are
required to be present at a high concentration to achieve
substantial efflux or uptake rates. They are likely to
need more association–dissociation events per transport
of substrate molecule (see Appendix for relationship of K
values to rate constants). In such cases, if the transport
efficiency defined by pi=Ki does not change on either side
of the membrane during the course of basal efflux of sub-
strates, then the steady state concentration of extracel-
lular DA, [DAo]t¼?, is purely a function of the DA con-












Thus if the steady state concentration of extracellular DA
does not vary linearly with the loading concentration, it
suggests either that K parameter values are not signifi-
cantly larger than the loading DA concentration or that
the transport efficiencies on either of the sides vary dur-
ing the transport. The transport efficiency could change
either because of a change in the number of transporters
with a favorable conformation for transport on the mem-
brane or because of a change in the binding efficiency of
the substrates with the respective transporters.
Second, if the binding affinity of DA for the inward-
facing DAT is very high (i.e., K1  {[DAt]–[DAo]}) and
that for the outward-facing DAT is low (i.e., K3 
[DAo]), then the time-dependent concentration of










and the steady state concentration of extracellular DA
would then be a constant and independent of the loaded





Third, if the binding affinity of DA for the outward-fac-
ing DAT is high (i.e., K3  [DAo]) and that for the
inward-facing DAT is low (i.e., K1  {[DAt]–[DAo]}),









According to Eq. 11, the concentration of extracellular
DA is either monotonically increasing or decreasing
with time depending upon the values of the parameters
involved.
High DA-transporter binding affinity (small K
values). If both the K parameter values are signifi-
cantly smaller than the respective DA concentrations,
then the extracellular DA concentration is a simple
monotonic function of time as given by
½DAo ¼ ðp1  p3Þt: ð12Þ
In such cases, the limiting phenomena in the transport
of DA from outside to inside or vice versa is not the
binding affinity but the maximal transport rates consti-
tuted by the total number of carriers and their rates of
switching conformations.
Equations 8–12 thus suggest useful tests to assess
the relative magnitude of K on either side of the cell
membrane.
AMPH-induced DA efflux
The middle term in Eq. 4 represents the efflux of DA
because of AMPH. If K1  a [AMPHo] þ {[DAt–[DAo]}
and if [AMPHo] remains constant (constant perfusion)
or decreases with time due to uptake (pulse stimula-
tion), then the rate of enhanced DA efflux following
AMPH stimulation should be monotonically decreas-
ing, assuming ~n is a constant throughout the efflux pro-
cess. But if ~n changes due to a change in the trans-
porter concentration on the cell membrane, then the
enhanced efflux rate may exhibit different kinetics.
The rate of change of ~n is quantitatively described by
Eq. 5. An analysis similar to that earlier provides use-
ful insights for the K value. If both the K values in Eq.
5 are much smaller than [AMPHi], then ~n is either line-
arly increasing or decreasing with time. If both K val-
ues are much larger than [AMPHi] and if [AMPHi]
increases with time due to uptake, then also ~n is either
monotonically increasing or decreasing. As a third pos-
sibility, if the relative magnitudes of the K values with
respect to [AMPHi] changes with time (i.e., at short
time periods following AMPH stimulation, K6, K7 
[AMPHi] and later, K6, K7  [AMPHi]), then ~n may
exhibit a maximum or a minimum. Following this,
when ~n exhibits a maximum, ~V6=K6 > ~V7=K7 at short
time intervals and ~V7 > ~V6 at longer time periods and
the signs reverse for the respective time intervals when
~n exhibits a minimum. This information is useful in
estimating values for V6, V7, K6, and K7.
Model testing
In this section, we demonstrate the applicability of
the model developed and analyzed earlier to DA release
experiments performed with or without external
AMPH stimulation. These experiments are designed to
facilitate estimation of the model parameters either
directly or indirectly. Later, we also illustrate the
AMPH-induced DAT trafficking effects by interpreting
the experimental results using our model.
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DA efflux rate rises and then falls in response to
continuous long-term AMPH stimulation
The amount of DA in the perfusate at 5 min intervals
in response to perfusion by 10 mMAMPH concentration is
shown in Figure 2a. It can be seen that the amount of DA
released in a 5-min interval increases and reaches a maxi-
mum and subsequently falls with time. Similar trends
were observed for other nonzero concentrations of AMPH
(data not shown). For comparison with the model, these
data were then converted into cumulative extracellular
DA amounts varying with time following AMPH stimula-
tion (Fig. 2b). This implies that AMPH entry into the cell
induces a time-dependent phenomenon that directly
affects the DA efflux profile. The rate of change of extrac-
ellular DA concentration eventually goes to zero. This
may imply either equal magnitudes of uptake and efflux
rates or the total shut-off of both processes, possibly due
to the absence of membrane-bound transporters.
Basal efflux parameters computed from efflux in
the absence of AMPH stimulation
Under zero-trans conditions, basal DA efflux (no AMPH)
also saturates with time (bottom curve in Fig. 2b). This is
consistent with a moderate to low DA-transporter binding
affinity, i.e., large K1 and/or K3 values, via Eqs. 8 or 9. We
then measured the steady state basal efflux of DA under
different DA loading concentrations, as shown in Figure 3.
The final released DA concentration is a linear function of
the loaded DA concentration. According to the analysis pre-
sented earlier, this suggests that K1  [DAi] and K3 
[DAo], and that the steady state concentration of extracel-
lular DA is described by Eq. 8.
Utilizing the restrictions on K1 and K3 determined
earlier, numerical values for the parameters associated
with basal DA efflux were computed from the transient
efflux data collected in the absence of AMPH stimula-
tion. The parameters p1, p3, K1, and K3 were deter-
mined by fitting Eq. 6 to the basal efflux data (Fig. 2b,
no AMPH). Since p1 and p3 represent lumped rate con-
stants determining the maximal transport rates of DA
to the inside and outside of the cell in the absence of
AMPH, we assumed that they are equal in magnitude.
However the affinities of DA to the outward-facing and
inward-facing DAT were allowed to be different, thus
resulting in different overall efficiencies of DA uptake
and efflux even in the absence of AMPH. The values
computed for p1, p3, K1, and K3 are shown in Table I.
Quantification of DAT trafficking
In our model, the parameter ~nðtÞ quantifies DAT traf-
ficking (see Eq. 5). Combined with the model, the ex-
perimental data can give a measure of DAT trafficking
upon AMPH stimulation. The time-varying profile of
~nðtÞ was extracted from our experimental data of time-
varying extracellular concentration of DA (Fig. 2b)
using
Fig. 3. The steady state concentration of released DA after basal
DA efflux follows a linear relation when plotted against the loaded
concentration with a regression coefficient R2 ¼ 0.9999 and a P-value
of 0.006 for the independent variable. The cells were loaded with ei-
ther 0.5, 1, or 5 lM [3H]DA for 10 min at 378C. After loading, the cells
were washed twice and then transferred to KRH buffer solution. The
radioactivity due to released DA in the buffer solution was then mea-




p1 ½DAt  ½DAof g
K1 þ ½DAt  ½DAof g
þ p2½AMPHo ½DAt  ½DAof g




The results of this computation are shown in Figure 4.
Note that ~nðtÞ exhibits a maximum around 15–25 min
following AMPH stimulation and that there is a 40%
increase in surface expression of DAT at the highest
concentration of AMPH tested (10 mM). This corre-
sponds to rapid surface mobilization of DAT initially
and then a rather slow internalization of DAT at longer
time periods following AMPH stimulation. Our find-
ings are consistent with the DAT trafficking observed
through direct visualization and measurement of sur-
face DAT (Johnson et al., 2005). In addition, from the
analysis described earlier, a maximum in the profile of
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~nðtÞ restricts the parameters to the range where
~V6=K6 > ~V7=K7 and ~V7 > ~V6. These guidelines were used
later in fitting the model to the experimental data.
Trafficking model fits AMPH-induced DA efflux
data better than existing model
The ability of the trafficking model (our model) and
that without trafficking (existing model) for AMPH-
induced DA efflux to fit the data of Figure 2b was
tested. In our continuous cell perfusion protocol,
because the extracellular concentration of AMPH was
maintained at a constant value (0, 1, 3, or 10 mM), Eq.
2 can be eliminated. In addition, Eq. A20 can be used
to approximate the intracellular AMPH concentra-
































   ð4Þ
where [AMPHo
*] is the value of the constant extracellu-
lar AMPH concentration maintained throughout the
experiment and b is a time constant defined in the
Appendix.
The experimental data on AMPH-induced DA efflux
were fitted to Eqs. 4 and 14 (Fig. 5). To do this, we held
the parameters describing basal efflux data at the val-
ues deduced earlier, and we constrained parameters
~V6, ~V7, K6, and K7 as described earlier. The parameters
were fitted to individual data sets (n ¼ 3) and then
averaged to give the final values used for generating
the model predictions in Figure 5. Table I lists the val-
ues of all 13 model parameters.
For comparison, the data of Figure 5 were also fit to a
model that does not include trafficking of transporters.
Equation 4 reflects the model without trafficking when
the parameter ~nðtÞ is treated as constant with a value
of unity. Since the basal efflux parameters should be
the same for this case, the same set of values of p1, K1,
p3, and K3 were used.
As seen in Figure 5, the concentration of extracellular
DA increases almost linearly with time initially and then
begins to plateau at a value dependent on the extracellu-
lar (constant) AMPH concentration. The trafficking-based
model shows excellent agreement with the experimental
data, while the model without trafficking of transporters
consistently underpredicts the extracellular DA concen-
tration, indicating that the assumption of constant mem-
brane-bound DAT concentration is inadequate to explain
efflux at longer time periods.
DISCUSSION
In this article, we test whether AMPH-induced DAT
reversal is sufficient to explain the enhanced DA efflux
following AMPH stimulation in hDAT-HEK cells
through quantitative modeling and analysis of DA
Fig. 4. The time-varying profile of ~nðtÞ, the membrane-bound DAT
concentration normalized to the initial (before AMPH stimulation)
membrane-bound DAT concentration, as extracted from the experi-
mental data of Figure 2b, using Eq. 13 for all nonzero values of time.
At t ¼ 0, ~nðtÞ was set at a value of 1. The data points represent the
mean values (n ¼ 3) and the lines are cubic polynomial fits of the data.
Fig. 5. AMPH-induced DA release data with model fits. Experi-
mental data (filled symbols with standard error of the mean as a verti-
cal error bar) were fitted to both the mathematical models—without
trafficking (dotted lines) and with trafficking (open symbols). The traf-
ficking model fits the data better than the model without trafficking
effects. For no trafficking model, Eq. 4 was used with constant value
of ~n ¼ 1. For trafficking model, Eq. 14 was solved simultaneously with
Eq. 4 with an initial value of ~n ¼ 1.
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efflux data. The excellent agreement between our
model and the experimental data on DA efflux in
response to continuous AMPH stimulation strongly
suggests the need to include the effects of AMPH on
DAT trafficking in assessing the effects of AMPH on
DA efflux. We report that the current quantitative
model for DA efflux, without the trafficking effects, con-
sistently underpredicts the extracellular DA concentra-
tion resulting from the efflux. Even a trafficking model
considering only the AMPH-induced internalization of
DAT, without considering the initial AMPH-induced
increase in surface DAT, would not be sufficient to
explain the experimentally observed trends of ~nðtÞ. We
further qualitatively substantiate the experimental ob-
servation of Johnson et al., (2005); in our model the sur-
face expression of DATundergoes a short-term increase
before it falls due to internalization.
Most investigations of the effects of AMPH on DA efflux
in isolated cell systems or synaptosomal preparations
measure short term or transient stimulation by AMPH
(Kahlig et al., 2005; Kantor et al., 2002; Khoshbouei et al.,
2004). To our knowledge, our data are the first measuring
DA efflux during a persistent stimulation by AMPH on
isolated cells. A longer stimulation by AMPH is physiolog-
ically relevant since the half-life of AMPH in the rat is 70
min and is 12 h in the human (Cho et al., 2001). Since
some of the effects of AMPH surface only after a longer
incubation time (>10 min), persistent stimulation for the
entire duration of the experiment enables us to see the
gradual unfolding of the dynamic events. In addition, the
persistent stimulation by AMPH creates a higher intracel-
lular concentration of AMPH, making AMPH-induced
DAT trafficking more pronounced. In vivo, a subcutane-
ous injection of AMPH in the rat results in elevated levels
of tissue AMPH for at least 60 min, although levels peak
at 30 min (Kuczenski et al., 1997).
The fitting of our experimental data to the model sup-
ports to some extent the facilitated exchange hypothesis
that inward transport of AMPH promotes an inward-fac-
ing conformation of DAT leading to enhanced outward
transport of DA. The relative measures of the different pa-
rameters provide very useful qualitative explanations.
The affinity of DA for the outward-facing DAT is about 8.5
times stronger than for the inward-facing DAT as noted
from the values of K1 and K3(K1/K3 ¼ 3500/410 ¼ 8.53).
The ratio (V/K) provides a measure of efficiency of the car-
rier-mediated transport. From the values listed in Table I,
it can be inferred that the efficiency of uptake process
(V3/K3 ¼ 0.028) is roughly 10 times greater than the basal
efflux of DA (V1/K1 ¼ 0.003). Both theoretical and experi-
mental studies confirm such an asymmetry of transport
through the same transporter molecule (Chen and Justice
Jr, 2000; Khoshbouei et al., 2004; Sitte et al., 1998; Stein,
1986). Since DAT is primarily designed for uptake of DA
after synaptic transmission, these values are in good
agreement with the current understanding of DAT func-
tion. From the fitted value for b, the efficiency of AMPH
efflux (V5/K5 ¼ 0.1) is about 30 times greater than that of
DA. Hence, it can be easily inferred that under basal con-
ditions, DA has less tendency than AMPH to be released
through DAT. If reversal of DAT conformation were to be
the only effect of AMPH on DAT-mediated DA transport
(facilitated exchange theory), then the efflux of DAwould
not be substantial as DA is still not the preferred sub-
strate for efflux in the presence of AMPH. Also, in purely
transporter-mediated exchange, the DA efflux would hap-
pen concurrently with the uptake of AMPH. Since the ini-
tial intracellular and extracellular concentrations of
AMPH are zero andmaximum, respectively, in our experi-
ments, the transporter-mediated AMPH uptake rate is
expected to be maximal at the beginning. Our recent
experiments of AMPH uptake (unpublished results) also
confirm this. However, our experimental data (Fig. 2a)
indicate that the DA efflux goes through a maximum 15–
25 min after AMPH stimulation. This suggests that facili-
tated exchange alone cannot explain the temporal efflux
profile of DA following AMPH stimulation. We explain
this inadequacy by suggesting that AMPH affects DA
transport by mediating time-dependent changes in DAT
expression on the membrane.
Our transporter trafficking model captures the data
seen in Figure 4. According to our model, upon entering
the cell, AMPH interferes with the constitutive DAT
trafficking process by catalyzing increased surface
expression initially and then internalization. Specifi-
cally, we find that the normalized concentration of
DAT, ~nðtÞ, changes with time after AMPH stimulation,
going through a maximum around 15–25 min before
declining below the initial value after approximately
an hour. Recent data obtained in the Gnegy laboratory
demonstrated an increase in surface DAT in hDAT-
HEK cells very shortly after addition of AMPH
(Johnson et al., 2005). This AMPH-mediated increase
in surface DAT was detected both by biotinylation and
[3H]WIN35428 binding. The increases in surface DAT
were on the order of 50–80%, which are comparable to
the 40% increase in our experimentally-derived ~nðtÞ
(Fig. 4). In our experiments, since the outside AMPH
concentration is held constant, the intracellular AMPH
concentration is also expected to reach a constant value
after some time. In fact, the value of b obtained by
model fitting indicates that the intracellular AMPH
concentration reaches 95% of the steady state value in
15 min. We predict from the observation of the fitted
values of ~V6, K6, ~V7, and K7 that AMPH-induced sur-
face mobilization of DAT starts immediately after a
lower threshold of intracellular AMPH concentration is
reached and the regulated internalization operates af-
ter a slightly higher threshold of intracellular AMPH
concentration is reached. These predictions have been
verified in hDAT-HEK cells in the literature, using
techniques of biotinylation and confocal microscopy.
Johnson et al. (2005) reported rapid (30 s1 min)
increases in surface DAT in rDAT-GFP-HEK cells fol-
lowing incubation with 3 mM AMPH. Incubations with
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2 mM AMPH for 1 hr (Saunders et al., 2000) or 10 mM
AMPH for >10 min (Kahlig et al., 2004) resulted in a
robust internalization of hDAT from the surface of
hDAT-HEK cells. The use of advanced microscopic visu-
alization tools (confocal fluorescence microscopy, total
internal reflection microscopy) and single cell experi-
mental techniques to capture the trafficking of DAT
molecules and molecular transport in real time (Mason
et al., 2005; Troyer and Wightman, 2002) will undoubt-
edly give the best estimates of the constants in our
model.
The mechanism by which AMPH causes the active
redistribution of DAT is not known but may involve sec-
ond messengers, particularly protein kinases (Park et al.,
2003; Pristupa et al., 1998). Protein kinase C and intracel-
lular Ca2þ were found to be essential for AMPH action
(Gnegy et al., 2004; Kantor et al., 2001) and may affect
the trafficking of DAT as well as the ability of AMPH to
elicit efflux of DA. Protein kinase C is known to have pro-
found effects on internalization of DAT (see reviews,
Zahniser and Doolen, 2001; Zhang et al., 1997). Conven-
tional Ca2þ-dependent protein kinase C isotypes were
found to be important for the down regulation of hDAT
expressed in Xenopus oocytes (Doolen and Zahniser,
2002). Different isotypes of protein kinase C could medi-
ate both exocytotic and endocytotic trafficking of DAT.
Naþ,Kþ-ATPase is another transporter whose trafficking
is regulated biphasically by PKC through direct phospho-
rylation of the transporter at different sites by different
PKC isozymes (Budu et al., 2002; Efendiev et al., 1999).
Since the main focus of our modeling approach is to con-
struct a simple model that explains long term AMPH-
induced DA efflux data in nondopaminergic cells, it cannot
be claimed exhaustive. Some possible effects of AMPH are
ignored either as a compromise for simplicity of the model or
as a consideration of their relative insignificance. For exam-
ple, AMPH, being lipophilic, can also diffuse through the
plasma membrane and produce changes in the intracellular
and extracellular DA concentration (Mack and Bonisch,
1979; Romanenko et al., 1998). But such passive transport
causes only an increase in the intracellular concentration of
AMPH and does not contribute to the reversal of DAT
because there would be no build-up of intracellular Naþ at
the inner face of the transporter (Khoshbouei et al., 2003; Pifl
and Singer, 1999). AMPH has been shown to cause changes
in intracellular pH (Sulzer et al., 1993). However, it is still
unresolved if the pH change specifically affects DAT-medi-
ated monoamine transport and so we did not include that in
ourmodel. In dopaminergic cells,where intracellularDA con-
centration is tightly regulated by VMAT2 expressed on the
vesicular membrane, we would need to account for the
AMPH effects on VMAT2-mediated DA transport from the
vesicles. Since our HEK system does not express VMAT2, it
is not included in our model. The ability of AMPH to block
VMAT2 controls the maximal amount of DA that will be
released in response to AMPH, but DAT, not VMAT2, is
essential for AMPH’s ability to elicit outward transport of
DAT (Fon et al., 1997; Jones et al., 1998; Pifl et al., 1995).
Because a rapidAMPH-mediated increase inDATwas found
in synaptosomes as well as HEK cells (Johnson et al., 2005),
we anticipate that our model will be applicable in physiologi-
cal systems.
Though our model is semiempirical, it captures the
major features of AMPH-induced DA efflux. Since the
model is constructed from a Michaelis–Menton approach,
the parameters in the model are not specific to any experi-
mental technique. This provides the model with a wide
range of applicability and testability, including informing
the design of particular experiments to test different
hypotheses. The experimental design in this article
requires only the measurement of extracellular concentra-
tion of DA over time. Combined with the knowledge of few
initial conditions, our model provides a simple and an
effective way to test the role of DAT trafficking in DA
release.
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APPENDIX
AMPH-induced DA release kinetic model
The derivation of the ordinary differential equations
describing the change in extracellular concentration of DA
and AMPH with time is explained in this section. It is
based on the transporter theory developed byStein (1986).
For a simple uptake or release of a substrate (e.g.,
DA) through a membrane-bound transporter (e.g.,












where DA on the intracellular side (denoted by the sub-
script \i") binds reversibly to the inward-facing conforma-
tion of DAT existing in a dynamic equilibrium with the
outward-facing conformation. DA then dissociates reversi-
bly from the outward-facing transporter. The sequence
will reverse for the uptake of DA from the outside the cell.
By writing out the rate equations based on law of mass
action, the rate of release of DA from inside to outside for





















This can be written in typical Michaelis–Menton form
as d½DAo=dt¼ðVmax½DAiÞ=ðKmþ½DAiÞ where Vmax
¼ k2½DATt and Km¼ð k2=kfð Þ k1=k1ð ÞÞþð k1=k1ð Þ
 kf=kfð ÞÞþ k2=k1ð Þ
For simultaneous transport of two substrates
through the same transporter, we follow the scheme of
Stein (1986). The kinetic scheme for the simultaneous
transport of AMPH and DA through DAT (4-state
model) is illustrated in Figure 1b.
For the scheme in Figure 1b, we have
½DATo
½DATt

























¼ f1½AMPHik2b2 þ k1f2½AMPHog2 þ g2f1½AMPHik2 þ g2f1f2½AMPHo½AMPHi

ðA2fÞ
where, S ¼ sum of numerators of the right hand side of
all the six Eqs. A2a–A2f.
Following the method of analysis suggested by Brit-
ton (1977), the unidirectional flux from inside to out-























B1B2 þ B2h1 þ h2B1
½DATt




For zero trans conditions, the initial concentration of
DAo will be zero and even during the course of release,
the value of DAo is very low. Also, there is no intracellu-
lar AMPH initially. Considering all these, Eq. A4 sim-


















1 ¼ ðh1B2k2 þ B1B2k2 þ h2B1k2 þ g1b2k2 þ b2b1k2
þ b1g2k2Þ
F1h1B2






B1B2 þ B2h1 þ h2B1
½DATt ðA7Þ




1 ¼ h1B2k1 þ B1B2k1 þ g2b1k1 þ g1b2k1 þ b2b1k1
þ b1g2k1 þ h1B2k2 þ B1B2k2 þ h2B1k2
þ g1b2k2 þ b2b1k2 þ b1g2k2 ðA8Þ
a
0 ¼ f2ðg2b1 þ k1b1 þ h1k1 þ k1g2Þ ðA9Þ
b ¼ F1ðh1B2 þ k2B2 þ h2k2 þ k2h1Þ þ h2F2k1: ðA10Þ
Equation A5 can be written as the sum of two terms,
thereby uncoupling the basal DA release and the










































K1 þ a½AMPHo þ ½DAi
: ðA11aÞ
Normalizing the concentration of membrane-bound
DAT at any point of time to that at time t ¼ 0 in the ear-

















ðh1B2k2 þ B1B2k2 þ h2B1k2 þ g1b2k2 þ b2b1k2 þ b1g2k2Þ F1h1B2B1B2þB2h1þh2B1 ½DATtt¼0

























Intracellular concentration of AMPH
In our AMPH perfusion experiments, the extracellu-
lar AMPH concentration was maintained constant. The
intracellular concentration of AMPH will eventually
reach a constant steady state value after some finite
time of DAT-mediated transport. A simple expression
for this steady state concentration of intracellular
AMPH can be deduced as follows:
Rate of increase of intracellular AMPH following








Since [AMPHi] is significantly smaller than K5, this












where [AMPH*o] is the constant outside concentration
of extracellular AMPH.









where b ¼ V5K5.
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